Back to Stocks

CRVS

Corvus Pharmaceuticals, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Corvus Pharmaceuticals has successfully transitioned into a well-capitalized clinical catalyst machine, underpinned by a massive liquidity boost. The company's recent follow-on public offering provided $189.4 million in net proceeds, bringing total liquidity to $236.7 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the apparent cash cushion, Corvus faces a precarious financial future characterized by high burn rates and looming contingent liabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CRVS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a critical inflection point, where a massive capital infusion has bought the time necessary to reach binary clinical milestones. The shift from a cash-constrained entity to one with $236.7 million in liquidity fundamentally changes the risk profile, though the underlying operational losses continue. The core tension for investors lies in whether the clinical success of soquelitinib can materialize before the current cash reserves are depleted by the escalating costs of Phase 3 trials. Ultimately, Corvus is a high-beta play on the ITK inhibition platform. While the financial architecture is now more robust, the company remains a pre-revenue entity with a high burn rate. The upcoming data read-outs for soquelitinib in both oncology and immunology will serve as the ultimate arbiter of value, determining if the current valuation is a floor or a ceiling for the stock.

Selected Quarter

Core Takeaway

Corvus has solved its immediate funding crisis, shifting the investor focus entirely to the clinical success of soquelitinib.

Investor Lens

The trade-off is between the high-conviction clinical data and the risk of significant future dilution to fund commercialization.

Watch Next

Data read-outs from the potentially registrational Phase 3 trial of soquelitinib in relapsed PTCL.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%
bullishMay 7

Raised $189.4 million via follow-on offering, extending runway to Q2 2028.

capital raise
90%
bearishMay 7

Reported a quarterly net loss of $13.7 million due to ongoing R&D spend.

earnings miss
40%
bearishMay 7

R&D expenses increased by $3.7 million YoY due to expanded clinical trial activity.

margin compression
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company at a critical inflection point, where a massive capital infusion has bought the time necessary to reach binary clinical milestones. The shift from a cash-constrained entity to one with $236.7 million in liquidity fundamentally changes the risk profile, though the underlying operational losses continue. The core tension for investors lies in whether the clinical success of soquelitinib can materialize before the current cash reserves are depleted by the escalating costs of Phase 3 trials. Ultimately, Corvus is a high-beta play on the ITK inhibition platform. While the financial architecture is now more robust, the company remains a pre-revenue entity with a high burn rate. The upcoming data read-outs for soquelitinib in both oncology and immunology will serve as the ultimate arbiter of value, determining if the current valuation is a floor or a ceiling for the stock.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.